

July 2, 2026

**BrightPath Submits IND Application to U.S. FDA
for the First-in-human Phase 1 Trial of BP2202**

Tokyo, Japan – July 2, 2026/ -- BrightPath Biotherapeutics Co., Ltd. ("BrightPath", TSE Growth 4594), a clinical-stage biopharmaceutical company developing next generation cell therapies for cancer therapeutics, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for BP2202, the Company's lead investigational allogeneic CAR-iNKT cell therapy. The IND supports the initiation of a first-in-human Phase 1 clinical trial of BP2202, iPS cell-derived BCMA CAR-iNKT cell therapy, in patients with relapsed or refractory multiple myeloma in the United States.

BP2202 is an off-the-shelf, induced pluripotent stem (iPS) cell-derived CAR-invariant natural killer T (iNKT) cell therapy targeting B-cell maturation antigen (BCMA), a clinically validated target for the treatment of multiple myeloma. The product is designed to combine the advantages of iPS cell technology with the unique biological properties of iNKT cells, with the goal of providing a potent, readily available treatment option for patients with multiple myeloma, which remains difficult to cure.

"The submission of our IND marks a defining development milestone for BrightPath as we advance this program into the clinic," said Kenichi Nagai, Chief Executive Officer of BrightPath Biotherapeutics, "BP2202 represents the first clinical application of our proprietary iPS cell-derived CAR-iNKT platform and reflects years of innovation in developing next-generation allogeneic cell therapies. We look forward to working closely with the FDA and initiating our first-in-human clinical trial."

This program has been designated as an orphan drug for multiple myeloma by the FDA in July 2025.

About BrightPath Biotherapeutics: BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies. For more information, visit www.brightpathbio.com/English

Investor and Media Contact:

Administration Department, BrightPath Biotherapeutics Co., Ltd.

E-mail: irpr@brightpathbio.com

<https://www.brightpathbio.com/English/>